Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
NAGE EBITDA Margin
EBITDA as a percentage of revenue.
Niagen Bioscience IncNASDAQ: NAGE
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 22.3%
EBITDA Margin was 22.3% in Q1 FY2026, up 4.0 pp from a year earlier. On a trailing-twelve-month basis it was 16.4%, up 1.5 pp year over year. Over 3 fiscal years it widened by 35.5 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 6.2% for the fiscal year ending Dec 2026, down from 15.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 22.3%+6.7 pp QoQ
- Last fiscal yearDec 2025
- 15.2%+4.8 pp YoY
- LTMMar 2026
- 16.4%+1.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.0 pp | -8.9 pp | -12.8 pp |
| 1 year | +4.8 pp | -9.0 pp | -13.8 pp |
| 3 years | +35.5 pp | -5.6 pp | -41.1 pp |
| 5 years | +4.2 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 15.2%
- Year-over-year change
- +4.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.2% | +4.8pp |
| FY2024 | 2024-12-31 | 10.4% | +14.2pp |
| FY2023 | 2023-12-31 | -3.9% | +16.5pp |
| FY2022 | 2022-12-31 | -20.3% | +17.4pp |
| FY2021 | 2021-12-31 | -37.7% | — |
EBITDA Margin vs competitors
How NAGE compares with its peers on the latest reported figures
- NAGE's LTM Mar 2026 EBITDA Margin of 16.4% is the 3rd highest of the 8 companies compared; the peer median is -101.1%.
- Its year-over-year change of +1.5 pp is the 3rd highest of 7, against a peer median of -25.3 pp.
- Over three fiscal years its change of +35.5 pp compares with a peer median of +89.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 114.9% | +263.4 pp | +343.9 pp | |
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | 16.4% | +1.5 pp | +35.5 pp |
| LTM Mar 2026 | -2.5% | -5.1 pp | +8.2 pp | |
| LTM Dec 2025 | -101.1% | — | — | |
| LTM Mar 2026 | -129.0% | -45.6 pp | -1804.0 pp | |
| LTM Mar 2026 | -261.2% | -183.0 pp | +138.5 pp | |
| LTM Mar 2026 | -267.4% | -282.4 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NAGE) | -101.1% | -25.3 pp | +89.5 pp | |
Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 67.45M | 72.05M | 83.57M | 99.6M | 129.42M |
| Cost of Revenue | 25.96M | 29.25M | 32.79M | 38.01M | 46.23M |
| Gross Profit | 41.49M | 42.8M | 50.78M | 61.59M | 83.19M |
| Gross Margin | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Research & Development | 3.83M | 4.83M | 4.96M | 6.02M | 6.33M |
| Selling, General & Admin | 64.73M | 56.6M | 51.42M | 47.84M | 62.56M |
| Operating Expenses | 68.56M | 61.43M | 56.38M | 53.86M | 68.89M |
| Depreciation & Amortization | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| EBITDA | (25.45M) | (14.66M) | (3.23M) | 10.34M | 19.64M |
| EBITDA Margin | -37.7% | -20.3% | -3.9% | 10.4% | 15.2% |
| Operating Income | (27.07M) | (18.63M) | (5.6M) | 7.73M | 14.3M |
| Operating Margin | -40.1% | -25.9% | -6.7% | 7.8% | 11.0% |
| Interest Income | 0 | 3K | 661K | 1.13M | 2.13M |
| Interest Expense | 55K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (55K) | 2.09M | 661K | 1.13M | 3.9M |
| Income Before Tax | (27.13M) | (16.54M) | (4.94M) | 8.86M | 18.19M |
| Pre-Tax Margin | -40.2% | -23.0% | -5.9% | 8.9% | 14.1% |
| Income Tax Expense | 0 | 0 | 0 | 305K | 810K |
| Net Income | (27.13M) | (16.54M) | (4.94M) | 8.55M | 17.38M |
| Net Margin | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% |
| EPS (Basic) | (0.40) | (0.24) | (0.07) | 0.10 | 0.22 |
| EPS (Diluted) | (0.40) | (0.24) | (0.07) | 0.11 | 0.20 |
| Weighted Avg Shares | 67.19M | 68.92M | 70.54M | 85.42M | 79.18M |
| Weighted Avg Shares (Diluted) | 67.19M | 69.73M | 74.99M | 79.72M | 85.44M |
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.